Dividend Power Score
A single, comprehensive score designed to measure the true strength of a company’s dividend.
This score combines three essential pillars of dividend quality:
Consistency – Measures how reliable the dividend has been over time, focusing on payment history, stability, and the absence of cuts or suspensions.
Payability – Assesses the company’s financial ability to sustain its dividend, taking into account cash flow, earnings coverage, balance sheet strength, and overall financial health.
Growth – Evaluates the long-term growth of both the dividend and the company’s share price, highlighting businesses that consistently increase payouts while creating shareholder value.
Higher scores identify companies that have historically delivered dependable income alongside sustained dividend growth and long-term capital appreciation.
Company Overview
3SBio Inc. is a biopharmaceutical company focused on the research, development, manufacturing, and commercialization of biologic therapies and selected small‑molecule drugs. The company operates primarily within the biopharmaceuticals and biotechnology industries, with a concentration on therapeutic areas such as nephrology, oncology, autoimmune diseases, and inflammation. Its core revenue is driven by proprietary biologics, biosimilars, and licensed products sold mainly through hospital channels in China.
The company is best known for its leadership position in recombinant protein therapeutics in China, particularly erythropoietin (EPO) products and tumor necrosis factor (TNF) inhibitors. 3SBio was founded in 1993 and has evolved from a domestic biologics manufacturer into a vertically integrated biopharmaceutical group with in‑house R&D, biologics manufacturing capabilities, and a nationwide sales network. Over time, it expanded its portfolio through internal development and acquisitions, strengthening its position in China’s biologics market.
Business Operations
3SBio’s operations are organized around its biopharmaceutical products segment, which encompasses biologics, biosimilars, and selected chemical drugs. Key marketed products include recombinant human erythropoietin for anemia treatment and the etanercept biosimilar used for autoimmune diseases. Revenue is primarily generated through product sales to public hospitals and healthcare institutions, with pricing and volumes influenced by China’s centralized procurement and reimbursement systems.
The company conducts R&D, manufacturing, and commercialization largely in‑house, supported by proprietary biologics platforms and production facilities that comply with Chinese regulatory standards. Its operating structure includes wholly owned and controlled subsidiaries such as Shenyang Sunshine Pharmaceutical Co., Ltd. and Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd., which play central roles in biologics development and manufacturing. Data on material joint ventures beyond these core subsidiaries is inconclusive based on available public sources.
Strategic Position & Investments
Strategically, 3SBio focuses on expanding its biologics pipeline, improving manufacturing efficiency, and strengthening its presence in high‑value therapeutic areas such as immunology and oncology. Growth initiatives emphasize lifecycle management of existing biologics, development of next‑generation biologics and biosimilars, and selective in‑licensing or acquisitions to complement internal R&D.
A notable strategic move was the acquisition and integration of Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd., which brought the etanercept biosimilar franchise into the group and reinforced its immunology portfolio. The company continues to invest in biologics manufacturing capacity and early‑stage research programs, though detailed disclosures on emerging technologies outside its core biologics focus are limited in public filings.
Geographic Footprint
3SBio’s operations are concentrated primarily in Mainland China, which represents the vast majority of its revenue and operational footprint. The company is headquartered in China, with manufacturing facilities, R&D centers, and a nationwide commercial organization serving hospitals across multiple provinces.
Internationally, 3SBio has limited direct commercial presence and does not report material overseas sales compared with its domestic business. Its global exposure is mainly indirect, through sourcing of equipment, limited out‑licensing activities, and adherence to international biologics manufacturing standards rather than through large‑scale foreign operations.
Leadership & Governance
3SBio was founded by Lou Jing, who has played a central role in shaping the company’s long‑term focus on biologics and vertically integrated operations. The leadership team emphasizes disciplined capital allocation, strong execution in regulated hospital markets, and sustained investment in biologics R&D as core elements of its strategic vision. The company operates under a board‑led governance structure consistent with Hong Kong–listed company requirements.
Key executives include:
- Lou Jing – Chairman
- Zhang Feng – Chief Executive Officer
- Wang Qiang – Chief Financial Officer
- Sun Lei – Chief Operating Officer
Certain executive role details may vary slightly across disclosures; data inconclusive based on available public sources for exact start dates and scope of responsibilities.